We are live on ! Find out more
AXN

Aoxing Pharmaceutical Company Inc.
AXN

Delisted

AXN was delisted on the 16th of October, 2017.

14 hedge funds and large institutions have $262K invested in Aoxing Pharmaceutical Company Inc. in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

40% more funds holding

Funds holding: 1014 (+4)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

93% less capital invested

Capital invested by funds: $3.53M → $262K (-$3.26M)

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.37%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
2
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
VKH
1
Virtu KCG Holdings
New York
$79K +$49.4K +39,328 +50%
BFA
2
BlackRock Fund Advisors
California
$68K -$1.71K -1,362 -1%
Bank of New York Mellon
3
Bank of New York Mellon
New York
$35K +$65.6K +52,227 New
UBS Group
4
UBS Group
Switzerland
$22K +$40.5K +32,224 New
RCM
5
Rotella Capital Management
Washington
$17K -$7.69K -6,121 -20%
Citadel Advisors
6
Citadel Advisors
Florida
$12K +$21.7K +17,304 New
EWM
7
Evercore Wealth Management
New York
$9K
Creative Planning
8
Creative Planning
Kansas
$7K +$12.6K +10,000 New
BIM
9
BlackRock Investment Management
Delaware
$5K +$720 +573 +9%
MA
10
MUFG Americas
New York
$4K +$7.65K +6,090 New
Deutsche Bank
11
Deutsche Bank
Germany
$3K -$13.5K -10,742 -68%
Citigroup
12
Citigroup
New York
$1K
SM
13
Sabby Management
Florida
-$3.16M -2,134,054 Closed
CK
14
Carnick & Kubik
Colorado
-$222 -150 Closed
JP Morgan Chase
15
JP Morgan Chase
New York
+$39 +31 New
BlackRock
16
BlackRock
New York
+$45 +36 New

AXN Hedge Fund Activity: Q4 2015 in Review

14 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q4 2015, worth a combined $262K — down 93% from $3.53M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AXN positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $65.6K. The largest seller was Sabby Management, exiting entirely with an estimated $3.16M sold.

  • 14 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q4 2015, up from 10 in Q3 2015.
  • Funds reported $262K of Aoxing Pharmaceutical Company Inc. stock for Q4 2015, down 93% quarter-over-quarter.
  • 7 funds opened new Aoxing Pharmaceutical Company Inc. positions in Q4 2015 and 3 closed out, a net change of +4 holders.
  • The largest Aoxing Pharmaceutical Company Inc. buyer in Q4 2015 was Bank of New York Mellon, an estimated $65.6K added.
  • The largest Aoxing Pharmaceutical Company Inc. seller in Q4 2015 was Sabby Management, an estimated $3.16M sold.

Based on aggregated 13F filings for Q4 2015.